-
Patient Rating
4.8 /5( out of 119 reviews )The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.
The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient Comments
Patient comments are gathered from our patient experience survey and displayed in their entirety.
Patients are de-identified for confidentiality and patient privacy.October 10, 2024HUNTSMAN CANCER CENTERknowledgeable and thorough
October 09, 2024HUNTSMAN CANCER CENTERShe is a fabulous Doctor! I am so appreciative of her care and guidance!
September 23, 2024HUNTSMAN CANCER CENTERTheir was a misunderstanding on our part as to the change in the rescheduling. As we were driving from Idaho, she adjusted to us coming late.
September 07, 2024SUGAR HOUSE HEALTH CENTERDr Chittoria is an awesome doctor. She listens, she understands how you feel, and she lets you be a part of your treatment. Every time I go to see her I'm so happy that she is my doctor. She knows what she's doing and how to do it.
July 28, 2024SUGAR HOUSE HEALTH CENTERAmazing doctor!
July 20, 2024SUGAR HOUSE HEALTH CENTERWonderful, caring doctor.
July 04, 2024HUNTSMAN CANCER CENTERDr.Chittoria is always kind and compassionate. Listens carefully to anything you say, and includes you in your treatment. She has an understanding heart, and treats each patient as if they were her only one that day. She is a very considerate doctor, with a wonderful sense of humor. Makes you feel better just to be with her. I have every confidence in her and her decisions. She is so good at explaining your treatment, and how it will affect your life, while helping you to understand why it is necessary. She gives me hope that I can get better.
July 01, 2024SUGAR HOUSE HEALTH CENTERDr. Chittoria is amazing. She is very knowledgeable but also very kind and caring.
June 28, 2024HUNTSMAN CANCER CENTERShe was excellent at explaining my options, and past results of trials..so that I could make a decision regarding how I wanted to proceed.
-
Board Certification and Academic Information
Academic Departments Internal Medicine -Primary Academic Divisions Oncology
Education history
Fellowship Experimental Therapeutics - Cleveland Clinic Foundation Fellow Fellowship Medical Oncology - University of Texas Health Science Center Fellow Fellowship Palliative Medicine and Hospice - University at Buffalo Fellow Residency Internal Medicine - SUNY Upstate Medical University Resident Residency Internal Medicine - King George’s Medical University Resident Professional Medical Medicine - King George’s Medical University M.B.B.S. Selected Publications
Journal Article
- Covington MF, Hoffman JM, Morton KA, Buckway B, Boucher KM, Rosenthal RE, Porretta JM, Brownson KE, Matsen CB, Vaklavas C, Ward JH, Wei M, Buys SS, Chittoria N, Yakish ED, Archibald ZG, Burrell LD, Butterfield RI, Yap JT (2023). Prospective Pilot Study of (18)F-Fluoroestradiol PET/CT in Patients With Invasive Lobular Carcinomas. AJR Am J Roentgenol, 221(2), 228-239. (Read full article)
-
Clinical Trials
- Randomized, Open-Label, Phase III Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician?s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
- Randomized, Open-Label, Phase III Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician?s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
- Randomized, Open-Label, Phase III Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician?s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
- Randomized, Open-Label, Phase III Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician?s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
- Randomized, Open-Label, Phase III Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician?s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
- Randomized, Open-Label, Phase III Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician?s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
- Randomized, Open-Label, Phase III Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician?s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy